Showing results (371-380 of 425) with videos related to
Sort By:
Pageof 43
NPJ Breast Cancer|May 10, 2022
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancerAdrienne G Waks, Neelam V Desai, Tianyu Li, et al.Journal of Geriatric Oncology|September 26, 2022
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancerRachel A Freedman, Tianyu Li, Mina S Sedrak, et al.The Journal of Biological Chemistry|May 5, 2017
Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cellsCeline Kerros, Satyendra C Tripathi, Dongxing Zha, et al.The Oncologist|June 4, 2026
Multidisciplinary Clinics in Cancer-Models, Metrics, and Meaning: A ReviewSeohyuk Lee, Jim W Doolin, David E Avigan, et al.Nature Communications|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2025
Novel Postneoadjuvant Prognostic Breast Cancer Staging SystemDavid J Winchester, Lavisha Singh, Stephen B Edge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary DissectionAbigail S Caudle, Wei T Yang, Savitri Krishnamurthy, et al.Plos One|September 2, 2015
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient OutcomesPriscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2020
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast CancerRomualdo Barroso-Sousa, Tanya E Keenan, Sonia Pernas, et al.JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.Pageof 43